Skip to main content

Articles

Page 4 of 25

  1. While still controversial, it has been demonstrated that vascular defects can precede the onset of other AD hallmarks features, making it an important therapeutic target. Given that the protein transthyretin (...

    Authors: Tiago Gião, Joana Saavedra, José Ricardo Vieira, Marta Teixeira Pinto, Gemma Arsequell and Isabel Cardoso
    Citation: Alzheimer's Research & Therapy 2021 13:143
  2. Varoglutamstat (formerly PQ912) is a small molecule that inhibits the activity of the glutaminyl cyclase to reduce the level of pyroglutamate-A-beta (pGluAB42). Recent studies confirm that pGluAB42 is a partic...

    Authors: E. G. B. Vijverberg, T. M. Axelsen, A. R. Bihlet, K. Henriksen, F. Weber, K. Fuchs, J. E. Harrison, K. Kühn-Wache, P. Alexandersen, N. D. Prins and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2021 13:142
  3. To explore whether the combination of white matter hyperintensities (WMHs) and amyloid-beta (Aβ) deposition is associated with worse cognitive performance on cognitive composites (CCs) domain scores in individ...

    Authors: G. Ortega, A. Espinosa, M. Alegret, GC. Monté-Rubio, O. Sotolongo-Grau, A. Sanabria, JP. Tartari, O. Rodríguez-Gómez, M. Marquié, A. Vivas, M. Gómez-Chiari, E. Alarcón-Martín, A. Pérez-Cordón, N. Roberto, I. Hernández, M. Rosende-Roca…
    Citation: Alzheimer's Research & Therapy 2021 13:141
  4. Alzheimer’s disease, among other neurodegenerative disorders, spans decades in individuals’ life and exhibits complex progression, symptoms and pathophysiology. Early diagnosis is essential for disease prevent...

    Authors: Valentina Escott-Price and Karl Michael Schmidt
    Citation: Alzheimer's Research & Therapy 2021 13:140

    The Correction to this article has been published in Alzheimer's Research & Therapy 2021 13:156

  5. Entrainment of neural oscillations in occipital cortices by external rhythmic visual stimuli has been proposed as a novel therapy for patients with Alzheimer’s disease (AD). Despite this increased interest in ...

    Authors: Alex I. Wiesman, Daniel L. Murman, Pamela E. May, Mikki Schantell, Sara L. Wolfson, Craig M. Johnson and Tony W. Wilson
    Citation: Alzheimer's Research & Therapy 2021 13:139
  6. Changes in grey matter covariance networks have been reported in preclinical and clinical stages of Alzheimer’s disease (AD) and have been associated with amyloid-β (Aβ) deposition and cognitive decline. Howev...

    Authors: Wiesje Pelkmans, Rik Ossenkoppele, Ellen Dicks, Olof Strandberg, Frederik Barkhof, Betty M. Tijms, Joana B. Pereira and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2021 13:138
  7. To systematically examine the clinical utility of tau-PET and Braak-staging as prognostic markers of future cognitive decline in older adults with and without cognitive impairment.

    Authors: Davina Biel, Matthias Brendel, Anna Rubinski, Katharina Buerger, Daniel Janowitz, Martin Dichgans and Nicolai Franzmeier
    Citation: Alzheimer's Research & Therapy 2021 13:137
  8. Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that has been neuropathologically diagnosed in brain donors exposed to repetitive head impacts, including boxers and American football, soc...

    Authors: Michael L. Alosco, Megan L. Mariani, Charles H. Adler, Laura J. Balcer, Charles Bernick, Rhoda Au, Sarah J. Banks, William B. Barr, Sylvain Bouix, Robert C. Cantu, Michael J. Coleman, David W. Dodick, Lindsay A. Farrer, Yonas E. Geda, Douglas I. Katz, Inga K. Koerte…
    Citation: Alzheimer's Research & Therapy 2021 13:136
  9. Perivascular spaces (PVS) have an important role in the elimination of metabolic waste from the brain. It has been hypothesized that the enlargement of PVS (ePVS) could be affected by pathophysiological mechan...

    Authors: Natalia Vilor-Tejedor, Iacopo Ciampa, Grégory Operto, Carles Falcón, Marc Suárez-Calvet, Marta Crous-Bou, Mahnaz Shekari, Eider M. Arenaza-Urquijo, Marta Milà-Alomà, Oriol Grau-Rivera, Carolina Minguillon, Gwendlyn Kollmorgen, Henrik Zetterberg, Kaj Blennow, Roderic Guigo, José Luis Molinuevo…
    Citation: Alzheimer's Research & Therapy 2021 13:135
  10. Understanding the changes that occur in the transitional stage between absent and overt amyloid-β (Aβ) pathology within the Alzheimer’s continuum is crucial to develop therapeutic and preventive strategies. The o...

    Authors: Marta Milà-Alomà, Mahnaz Shekari, Gemma Salvadó, Juan Domingo Gispert, Eider M. Arenaza-Urquijo, Grégory Operto, Carles Falcon, Natalia Vilor-Tejedor, Oriol Grau-Rivera, Aleix Sala-Vila, Gonzalo Sánchez-Benavides, José Maria González-de-Echávarri, Carolina Minguillon, Karine Fauria, Aida Niñerola-Baizán, Andrés Perissinotti…
    Citation: Alzheimer's Research & Therapy 2021 13:134
  11. We assessed the performance of plasma amyloid oligomerization tendency (OAβ) as a marker for abnormal amyloid status. Additionally, we examined long-term storage effects on plasma OAβ.

    Authors: Rosha Babapour Mofrad, Philip Scheltens, SangYun Kim, Sungmin Kang, Young Chul Youn, Seong Soo A. An, Jori Tomassen, Bart N. M. van Berckel, Pieter Jelle Visser, Wiesje M. van der Flier and Charlotte E. Teunissen
    Citation: Alzheimer's Research & Therapy 2021 13:133
  12. In the current study, we aimed to develop an algorithm based on biomarkers obtained through non- or minimally invasive procedures to identify healthy elderly subjects who have an increased risk of abnormal cer...

    Authors: Samantha Prins, Ahnjili Zhuparris, Ellen P. Hart, Robert-Jan Doll and Geert Jan Groeneveld
    Citation: Alzheimer's Research & Therapy 2021 13:132
  13. Many patients with Alzheimer’s disease (AD) are physically frail or have substantial functional impairments. There is growing evidence that such patients are at higher risk for medication-induced adverse event...

    Authors: M. Seibert, V. Mühlbauer, J. Holbrook, S. Voigt-Radloff, S. Brefka, D. Dallmeier, M. Denkinger, C. Schönfeldt-Lecuona, S. Klöppel and C. A. F. von Arnim
    Citation: Alzheimer's Research & Therapy 2021 13:131
  14. Leukocyte telomere length (LTL) has been shown to predict Alzheimer’s disease (AD), albeit inconsistently. Failing to account for the competing risks between AD, other dementia types, and mortality, can be an ...

    Authors: Fernanda Schäfer Hackenhaar, Maria Josefsson, Annelie Nordin Adolfsson, Mattias Landfors, Karolina Kauppi, Magnus Hultdin, Rolf Adolfsson, Sofie Degerman and Sara Pudas
    Citation: Alzheimer's Research & Therapy 2021 13:130
  15. We aimed to systematically describe the burden and distribution of white matter hyperintensities (WMH) and investigate correlations with neuropsychiatric symptoms in pathologically proven Alzheimer’s disease (...

    Authors: Philippe Desmarais, Andrew F. Gao, Krista Lanctôt, Ekaterina Rogaeva, Joel Ramirez, Nathan Herrmann, Donald T. Stuss, Sandra E. Black, Julia Keith and Mario Masellis
    Citation: Alzheimer's Research & Therapy 2021 13:129
  16. Cognitive reserve is most commonly measured using socio-behavioural proxy variables. These variables are easy to collect, have a straightforward interpretation, and are widely associated with reduced risk of d...

    Authors: R. Boyle, S. P. Knight, C. De Looze, D. Carey, S. Scarlett, Y. Stern, I. H. Robertson, R. A. Kenny and R. Whelan
    Citation: Alzheimer's Research & Therapy 2021 13:128
  17. Although social cognitive dysfunction is a major feature of frontotemporal dementia (FTD), it has been poorly studied in familial forms. A key goal of studies is to detect early cognitive impairment using vali...

    Authors: Hannah D. Franklin, Lucy L. Russell, Georgia Peakman, Caroline V. Greaves, Martina Bocchetta, Jennifer Nicholas, Jackie Poos, Rhian S. Convery, David M. Cash, John van Swieten, Lize Jiskoot, Fermin Moreno, Raquel Sanchez-Valle, Barbara Borroni, Robert Laforce Jr, Mario Masellis…
    Citation: Alzheimer's Research & Therapy 2021 13:127
  18. Blood circulating microRNAs that are specific for Alzheimer’s disease (AD) can be identified from differentially expressed microRNAs (DEmiRNAs). However, non-reproducible and inconsistent reports of DEmiRNAs h...

    Authors: Sze Chung Yuen, Xiaonan Liang, Hongmei Zhu, Yongliang Jia and Siu-wai Leung
    Citation: Alzheimer's Research & Therapy 2021 13:126
  19. Amyloid precursor protein (APP) processing is central to Alzheimer’s disease (AD) etiology. As early cognitive alterations in AD are strongly correlated to abnormal information processing due to increasing syn...

    Authors: Maria Mensch, Jade Dunot, Sandy M. Yishan, Samuel S. Harris, Aline Blistein, Alban Avdiu, Paula A. Pousinha, Camilla Giudici, Marc Aurel Busche, Peter Jedlicka, Michael Willem and Hélène Marie
    Citation: Alzheimer's Research & Therapy 2021 13:125
  20. In 2019, the Lewy Body Dementia Association formed an Industry Advisory Council to bring together a collaborative group of stakeholders with the goal of accelerating clinical research into Lewy body dementia t...

    Authors: Jennifer G. Goldman, Bradley F. Boeve, Melissa J. Armstrong, Doug R. Galasko, James E. Galvin, David J. Irwin, James B. Leverenz, Karen Marder, Victor Abler, Kevin Biglan, Michael C. Irizarry, Bill Keller, Robert Lai, Leanne Munsie, Michael Belleville, Ondrea Chaney…
    Citation: Alzheimer's Research & Therapy 2021 13:124
  21. Plasma biomarkers showed a promising value in the disease diagnosis and management of Alzheimer’s disease (AD). However, profiles of the biomarkers and the associations with cognition across a spectrum of cogn...

    Authors: Zhenxu Xiao, Xue Wu, Wanqing Wu, Jingwei Yi, Xiaoniu Liang, Saineng Ding, Li Zheng, Jianfeng Luo, Hongchen Gu, Qianhua Zhao, Hong Xu and Ding Ding
    Citation: Alzheimer's Research & Therapy 2021 13:123
  22. Genetic studies have primarily been conducted in European ancestry populations, identifying dozens of loci associated with late-onset Alzheimer’s disease (AD). However, much of AD’s heritability remains unexpl...

    Authors: Andréa R. V. R. Horimoto, Diane Xue, Timothy A. Thornton and Elizabeth E. Blue
    Citation: Alzheimer's Research & Therapy 2021 13:122
  23. Arterial stiffening has emerged as an important risk factor for Alzheimer’s disease (AD) and related dementias. Carotid-femoral pulse wave velocity has been proposed as a non-invasive and reproducible method t...

    Authors: Katherine J. Bangen, Denis S. Smirnov, Lisa Delano-Wood, Christina E. Wierenga, Mark W. Bondi, David P. Salmon and Douglas Galasko
    Citation: Alzheimer's Research & Therapy 2021 13:121
  24. There is an urgent need for objective markers of Alzheimer’s disease (AD)-related cognitive impairment in people with Down syndrome (DS) to improve diagnosis, monitor disease progression, and assess response t...

    Authors: Alberto Lleó, Maria Carmona-Iragui, Laura Videla, Susana Fernández, Bessy Benejam, Jordi Pegueroles, Isabel Barroeta, Miren Altuna, Silvia Valldeneu, Mei-Fang Xiao, Desheng Xu, Raúl Núñez-Llaves, Marta Querol-Vilaseca, Sònia Sirisi, Alexandre Bejanin, M. Florencia Iulita…
    Citation: Alzheimer's Research & Therapy 2021 13:119
  25. Impaired self-awareness of memory function, a.k.a. anosognosia, is a common symptom in Alzheimer’s disease (AD); however, its pathological correlates remain unclear. Here, we investigated the impact of amyloid...

    Authors: Geoffroy Gagliardi, Madeline Kuppe, Cristina Lois, Bernard Hanseeuw and Patrizia Vannini
    Citation: Alzheimer's Research & Therapy 2021 13:118
  26. Genome-wide association studies (GWAS) have identified a number of genetic variants for Alzheimer’s disease (AD). However, most GWAS were conducted in individuals of European ancestry, and non-European populat...

    Authors: Hang-Rai Kim, Sang-Hyuk Jung, Jaeho Kim, Hyemin Jang, Sung Hoon Kang, Song Hwangbo, Jun Pyo Kim, So Yeon Kim, Beomsu Kim, Soyeon Kim, Jee Hyang Jeong, Soo Jin Yoon, Kyung Won Park, Eun-Joo Kim, Bora Yoon, Jae-Won Jang…
    Citation: Alzheimer's Research & Therapy 2021 13:117
  27. Alzheimer disease (AD) is the most common cause of dementia. Preclinical AD is the period during which early AD brain changes are present but cognitive symptoms have not yet manifest. The presence of AD brain ...

    Authors: Sayeh Bayat, Ganesh M. Babulal, Suzanne E. Schindler, Anne M. Fagan, John C. Morris, Alex Mihailidis and Catherine M. Roe
    Citation: Alzheimer's Research & Therapy 2021 13:115
  28. Neuronal hyperactivity related to β-amyloid (Aβ) is considered an early warning sign of Alzheimer disease (AD). Although increasing evidence supports this opinion, the underlying mechanisms are still unknown.

    Authors: Yang Li, Ke Zhu, Ning Li, Xiaotong Wang, Xuansheng Xiao, Linying Li, Lijuan Li, Ying He, Jinglan Zhang, Jiaoyang Wo, Yanqiu Cui, Haixia Huang, Jianliang Zhang, Wei Wang, Xiaomin Wang and Yan Zheng
    Citation: Alzheimer's Research & Therapy 2021 13:114
  29. Although few studies have shown that risk factors for Alzheimer’s disease (AD) are associated with cognitive decline in AD, not much is known whether the impact of risk factors differs between early-onset AD (...

    Authors: Jaeho Kim, Sook-Young Woo, Seonwoo Kim, Hyemin Jang, Junpyo Kim, Jisun Kim, Sung Hoon Kang, Duk L. Na, Juhee Chin, Liana G. Apostolova, Sang Won Seo and Hee Jin Kim
    Citation: Alzheimer's Research & Therapy 2021 13:113
  30. The described relationship between Alzheimer’s disease (AD) and type 2 diabetes (T2D) and the fact that AD has no succesful treatment has led to the study of antidiabetic drugs that may limit or slow down AD p...

    Authors: Maria Vargas-Soria, Maria Jose Carranza-Naval, Angel del Marco and Monica Garcia-Alloza
    Citation: Alzheimer's Research & Therapy 2021 13:112
  31. Challenges have been recognized in healthcare of patients with Alzheimer’s disease (AD) in the COVID-19 pandemic, given a high infection and mortality rate of COVID-19 in these patients. This situation urges t...

    Authors: Nian Xiong, Martin R. Schiller, Jingwen Li, Xiaowu Chen and Zhicheng Lin
    Citation: Alzheimer's Research & Therapy 2021 13:111
  32. Dementia-like cognitive impairment is an increasingly reported complication of SARS-CoV-2 infection. However, the underlying mechanisms responsible for this complication remain unclear. A better understanding ...

    Authors: Yadi Zhou, Jielin Xu, Yuan Hou, James B. Leverenz, Asha Kallianpur, Reena Mehra, Yunlong Liu, Haiyuan Yu, Andrew A. Pieper, Lara Jehi and Feixiong Cheng
    Citation: Alzheimer's Research & Therapy 2021 13:110
  33. Language impairment is an important marker of neurodegenerative disorders. Despite this, there is no universal system of terminology used to describe these impairments and large inter-rater variability can exi...

    Authors: Anthony Yeung, Andrea Iaboni, Elizabeth Rochon, Monica Lavoie, Calvin Santiago, Maria Yancheva, Jekaterina Novikova, Mengdan Xu, Jessica Robin, Liam D. Kaufman and Fariya Mostafa
    Citation: Alzheimer's Research & Therapy 2021 13:109
  34. Subjective cognitive decline, perceived worsening of cognitive ability without apparent performance issues on clinical assessment, may be an important precursor to dementia. While previous cross-sectional rese...

    Authors: Raymond P. Viviano and Jessica S. Damoiseaux
    Citation: Alzheimer's Research & Therapy 2021 13:108
  35. Accelerated long-term forgetting has been identified in preclinical Alzheimer’s disease (AD) and is attributed to a selective impairment of memory consolidation in which the hippocampus plays a key role. As bl...

    Authors: Jianwei Yang, Chaojun Kong, Longfei Jia, Tingting Li, Meina Quan, Yan Li, Diyang Lyu, Fangyu Li, Hongmei Jin, Ying Li, Qigeng Wang and Jianping Jia
    Citation: Alzheimer's Research & Therapy 2021 13:107
  36. In preclinical studies, p38⍺ kinase is implicated in Alzheimer’s disease (AD) pathogenesis. In animal models, it mediates impaired synaptic dysfunction in the hippocampus, causing memory deficits, and is invol...

    Authors: Niels D. Prins, John E. Harrison, Hui-May Chu, Kelly Blackburn, John J. Alam and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2021 13:106
  37. Subjective cognitive decline (SCD) is the subjective perception of a decline in memory and/or other cognitive functions in the absence of objective evidence. Some SCD individuals however may suffer from very e...

    Authors: Federica Ribaldi, Christian Chicherio, Daniele Altomare, Marta Martins, Szymon Tomczyk, Ileana Jelescu, Enrique Maturana, Max Scheffler, Sven Haller, Karl-Olof Lövblad, Michela Pievani, Valentina Garibotto, Matthias Kliegel and Giovanni B. Frisoni
    Citation: Alzheimer's Research & Therapy 2021 13:105
  38. Alzheimer’s disease (AD) is a progressive and irreversible brain disorder. Hippocampus is one of the involved regions and its atrophy is a widely used biomarker for AD diagnosis. We have recently developed Den...

    Authors: Sreevani Katabathula, Qinyong Wang and Rong Xu
    Citation: Alzheimer's Research & Therapy 2021 13:104
  39. Old age, the most important risk factor for Alzheimer’s disease (AD), is associated with thermoregulatory deficits. Brown adipose tissue (BAT) is the main thermogenic driver in mammals and its stimulation, thr...

    Authors: Marine Tournissac, Tra-My Vu, Nika Vrabic, Clara Hozer, Cyntia Tremblay, Koralie Mélançon, Emmanuel Planel, Fabien Pifferi and Frédéric Calon
    Citation: Alzheimer's Research & Therapy 2021 13:103
  40. Neurofilament light in serum (sNfL) is a biomarker for axonal damage with elevated levels in many neurological disorders, including neurodegenerative dementias. Since within-group variation of sNfL is large an...

    Authors: E. A. J. Willemse, P. Scheltens, C. E. Teunissen and E. G. B. Vijverberg
    Citation: Alzheimer's Research & Therapy 2021 13:101
  41. Little is known about the heterogeneous etiology of suspected non-Alzheimer’s pathophysiology (SNAP), a group of subjects with neurodegeneration in the absence of β-amyloid. Using antemortem MRI and pathologic...

    Authors: L. E. M. Wisse, R. de Flores, L. Xie, S. R. Das, C. T. McMillan, J. Q. Trojanowski, M. Grossman, E. B. Lee, D. Irwin, P. A. Yushkevich and D. A. Wolk
    Citation: Alzheimer's Research & Therapy 2021 13:100
  42. Inconsistent positivity thresholds, image analysis pipelines, and quantitative outcomes are key challenges of multisite studies using more than one β-amyloid (Aβ) radiotracer in positron emission tomography (P...

    Authors: Sarah K. Royse, Davneet S. Minhas, Brian J. Lopresti, Alice Murphy, Tyler Ward, Robert A. Koeppe, Santiago Bullich, Susan DeSanti, William J. Jagust and Susan M. Landau
    Citation: Alzheimer's Research & Therapy 2021 13:99
  43. The Placebo Group Simulation Approach (PGSA) aims at partially replacing randomized placebo-controlled trials (RPCTs), making use of data from historical control groups in order to decrease the needed number o...

    Authors: Manfred Berres, Andreas U. Monsch and René Spiegel
    Citation: Alzheimer's Research & Therapy 2021 13:97
  44. The relationship between cancer and dementia is triggering growing research interest. Several preclinical studies have provided the biological rationale for the repurposing of specific anticancer agents in Alz...

    Authors: Antonio Ancidoni, Ilaria Bacigalupo, Giulia Remoli, Eleonora Lacorte, Paola Piscopo, Giulia Sarti, Massimo Corbo, Nicola Vanacore and Marco Canevelli
    Citation: Alzheimer's Research & Therapy 2021 13:96
  45. Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis, biomarker stat...

    Authors: Maitee Rosende-Roca, Carla Abdelnour, Ester Esteban, Juan Pablo Tartari, Emilio Alarcon, Juliana Martínez-Atienza, Antonio González-Pérez, María E. Sáez, Asunción Lafuente, Mar Buendía, Ana Pancho, Nuria Aguilera, Marta Ibarria, Susana Diego, Sara Jofresa, Isabel Hernández…
    Citation: Alzheimer's Research & Therapy 2021 13:95
  46. Alzheimer’s disease (AD) is a neurodegenerative disorder associated with extracellular amyloid-β peptide deposition and progressive neuron loss. Strong evidence supports that neuroinflammatory changes such as ...

    Authors: Freyja Aichholzer, Hans-Wolfgang Klafki, Isabella Ogorek, Jonathan Vogelgsang, Jens Wiltfang, Norbert Scherbaum, Sascha Weggen and Oliver Wirths
    Citation: Alzheimer's Research & Therapy 2021 13:94